What Is E2B(R3)? ICSR Reporting Guide for PV Teams
E2B(R3) is the ICH standard used to structure and electronically exchange Individual Case Safety Reports. For pharmacovigilance teams, it is not only a file format. It defines how source narratives, reporters, patients, products, reactions, seriousness criteria, assessments, and follow-up information are organized so safety data can move between companies, partners, and authorities with fewer manual interpretation gaps.
Why E2B(R3) matters for ICSR processing
An Individual Case Safety Report often starts as an email, call-center note, literature abstract, clinical narrative, or partner file. Before it can be reported, the team must identify the minimum valid case information, structure the case, code medical concepts, assess seriousness and causality, and prepare an exchange-ready record.
E2B(R3) gives that record a consistent structure. It supports electronic transmission of ICSR data elements and acknowledgement messages, which helps receiving systems validate and process cases. For teams handling case volumes across regions, this consistency is essential for triage, follow-up, reconciliation, duplicate detection, and submission readiness.
Core data domains in an E2B(R3) case
A complete ICSR includes more than the adverse event term. Teams typically need reporter information, patient characteristics, suspect and concomitant products, reaction details, seriousness and outcome data, medical history, laboratory information, narrative text, sender details, and case-level identifiers.
The operational challenge is preserving traceability between the original source text and each structured field. Reviewers need to see what was extracted, which term was selected, what was left unchanged, and which fields still require human confirmation.
Common preparation problems
Manual E2B(R3) preparation is vulnerable to inconsistent coding, incomplete source-to-field traceability, ambiguous follow-up handling, and late-stage validation failures. These issues become more expensive when they are found at the submission step instead of during intake.
A practical process should validate early: required fields, terminology status, date consistency, product and event relationships, seriousness logic, and narrative completeness should be checked before building the final exchange package.
Where the VigiHelp AI engine fits
VigiHelp supports AI pharmacovigilance ICSR processing by extracting safety information from verbatim narratives, preparing structured case fields, supporting MedDRA coding review, and helping reviewers identify missing or inconsistent information before downstream E2B(R3) workflows.
The goal is not to remove expert review. The goal is to reduce repetitive transcription, make review points explicit, and keep source evidence visible so qualified pharmacovigilance users can confirm, correct, and approve the case.
Official references
These official sources informed the regulatory and terminology context of this guide. Teams should always confirm current requirements against their own procedures and target authorities.
Evaluate VigiHelp for your pharmacovigilance workflow
Use representative cases to test adverse event extraction, MedDRA coding review, causality support, existing case quality control, and preparation for E2B(R3), CIOMS, ESG, or EudraVigilance-related workflows.
Request a demoBack to resources